

MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS



EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease:

A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
2. Blood vessels, Surgery.

- I. Fitridge, Robert
- II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters

Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre

Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1
Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)
2. Vascular smooth muscle structure and function 13
David Wilson (Adelaide, Australia)
3. Atherosclerosis 25
Gillian Cockerill, Qingbo Xu (London, UK)
4. Mechanisms of plaque rupture 43
Ian Loftus (London, UK)
5. Current and emerging therapies in atheroprotection 79
Stephen Nicholls, Rishi Puri (Cleveland, USA)
6. Molecular approaches to revascularisation in peripheral vascular disease 103
Greg McMahon, Mark McCarthy (Leicester, UK)
7. Biology of restenosis and targets for intervention 115
Richard Kenagy (Seattle, USA)
8. Vascular arterial haemodynamics 153
Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)
9. Physiological haemostasis 177
Simon McRae (Adelaide, Australia)
10. Hypercoagulable states 189
Simon McRae (Adelaide, Australia)
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201
Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)
12. Pathogenesis of aortic aneurysms 227
Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)
13. Pharmacological treatment of aneurysms 247
Matthew Thompson, Janet Powell (London, UK)
14. Aortic dissection and connective tissue disorders 255
Mark Hamilton (Adelaide, Australia)
15. Biomarkers in vascular disease 277
Ian Nordon, Robert Hincliffe (London, UK)
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295
Martin Veller (Johannesburg, South Africa)
17. SIRS, sepsis and multiorgan failure 315
Vishwanath Biradar, John Moran (Adelaide, Australia)
18. Pathophysiology of reperfusion injury 331
Prue Cowled, Robert Fitridge (Adelaide, Australia)
19. Compartment syndrome 351
Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)
20. Pathophysiology of pain 375
Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)

21. Postamputation pain 389
Stephan Schug, Gail Gillespie
(Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard
(Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin,
Lyle Moldauer, Robert Diegelmann
(Florida, USA)
 24. Pathophysiology and principles of
varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg
ulceration: Principles and vascular
biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of
management of the diabetic foot 475
David Armstrong, Timothy Fisher,
Brian Lepow, Matthew White,
Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics
and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton
(London, UK)
 29. Pathophysiology of vascular graft
infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular Ca^{2+}
- Sources of cytosolic Ca^{2+} entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction	43
Evidence for the ‘plaque rupture theory’	44
Coronary circulation	
Cerebral circulation	
The role of individual components of the arterial wall	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
The role of angiogenesis in plaque rupture	
The role of infectious agents in plaque rupture	57
Risk prediction of plaque instability	58
Imaging	
Blood markers	59
Therapy aimed at plaque stabilisation	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
Summary	62
References	63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background	79
Pathology	
Risk factor modification	80
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
Risk factor modification in the diabetic patient	89
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
Future targets	93
Conclusion	
References	94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction	103
Mechanisms of vascular growth	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
Therapeutic induction of vascular growth	107
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
Conclusions	110
References	

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

CHAPTER 10 – HYPERCOAGULABLE STATES

Simon McRae

Introduction 189

Classification of thrombophilia

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

Potential detrimental effects of thrombophilia testing 197

Conclusion

References

CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter*

Introduction 201

Platelet function – Adhesion and activation

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

Platelet function testing 215

Light-transmission aggregometry

Whole blood aggregometry 217
 VerifyNow® Assay
 Flow cytometry 218

References

CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,
 Paul E Norman*

Introduction 227

Differences between thoracic and abdominal aortic aneurysms 228

Summary of current theories and stages of AAA evolution

Atherosclerosis and AAA

Immune mechanisms in AAA 229

Extracellular matrix dysfunction 232

Infection 233

Biomechanical forces

Angiogenesis

Intra-luminal thrombus

Extracellular matrix proteolysis 234

Genetics 236

AAA rupture 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

Future research

References

CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

Matthew Thompson, Janet T Powell

Background 247

Screening programmes

Pathophysiology 248

Therapeutic strategies

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

Drugs acting on the renin/angiotensin axis

HMG Co-A reductase inhibitors 251

The future – Data from recent

experimental studies

References

CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

Mark Hamilton

Introduction 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

Classification of aortic syndromes

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

Pathogenesis of thoracic aortic dissection

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

Complications of acute aortic syndromes 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

Connective tissue disorders and acute aortic syndromes

Marfan syndrome
 Fibrillin and Marfan syndrome 265
 The role of transforming growth factor
 beta in development of the vascular
 system in health and disease 266
 Ehlers-Danlos syndrome 267
 Diagnosis of Ehlers-Danlos syndrome
 268
 Loeys-Deitz syndrome 270
 Familial thoracic aortic aneurysm disease
 271
 Bicuspid aortic valve 273
 Turners Syndrome
Summary 274
Reference list

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction 277
What is a biomarker?
Types of biomarkers
 A classical clinical example 278
**Potential value of biomarkers in vascular
 disease 279**
Biomarker discovery steps 280
AAA biomarkers
 Circulating extracellular matrix markers
 281
 Matrix-degrading enzymes 283
 Proteins associated with thrombosis
 Markers of inflammation 284
Biomarkers of AAA rupture 285
Biomarkers following endovascular repair
 Inflammation 287
 Lipid accumulation
 Apoptosis
 Thrombosis
 Proteolysis 288
Challenges in biomarkers discovery
Future work
Conclusion 289
References

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides 295
Introduction
Classification of vasculitides 296
Clinical presentation of vasculitides
Investigations of vasculitides
**Principles of treatment of vasculitides
 297**
**The vasculitides of specific interest to
 vascular surgeons 298**
 Giant cell arteritis
 Takayasu's arteritis 299
 Thromboangitis obliterans (Buerger's
 disease) 300
 Behcet's disease 301
 Polyarteritis nodosa 302
 Vasculitides secondary to connective
 tissue diseases 303
 Systemic lupus erythematosus (SLE)
 Antiphospholipid antibody syndrome
 (APS) 304
 Rheumatoid arthritis 305
 Scleroderma
 Infective vasculitides 306
 Human immunodeficiency virus (HIV)
**Pathophysiology and principles of
 Raynaud's phenomenon 307**
 Prevalence of Raynaud's phenomenon
 308
 Clinical findings in Raynaud's
 phenomenon 309
 Diagnosis of Raynaud's phenomenon
Prognosis 310
Treatment
Recommendations 311
References 312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multorgan dysfunction syndrome (MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 –
PATHOPHYSIOLOGY OF
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain components 396

Neuropharmacological therapies

Invasive therapies
 Electroconvulsive therapy (ECT)
 Nerve blockade
 Spinal cord stimulation
 Implantable intrathecal delivery systems
 Dorsal root entry zone (DREZ) lesions
 Psychological therapy 397

Future aims

References

CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN

Stephan Schug, Kathryn Stannard

Introduction 401

Principles of treatment

Pharmacological treatment 402

Opioids

Recommendations for clinical use of opioids

Tramadol

Mechanism of action

Efficacy 403

Adverse effects

Recommendations for clinical use of tramadol in neuropathic pain

Antidepressants

Tricyclic antidepressants (TCAs)

Mechanism of action 404

Adverse effects

Selective serotonin re-uptake inhibitors (SSRIs)

Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405

Recommendations for clinical use of antidepressants as analgesics

Anticonvulsants

Mechanism of action 406

Individual medications

Clonazepam

Gabapentin

Pregabalin 407

Carbamazepine

Sodium valproate 408

Phenytoin

Lamotrigene

Recommendations for clinical use of anticonvulsants as analgesics

Local anaesthetics and antiarrhythmics 409

Mechanism of action

Lignocaine

Mexiletine

Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain

N-methyl-D-aspartate-receptor antagonists (NMDA)

Ketamine 410

Other NMDA antagonists

Miscellaneous compounds for systemic use

Clonidine

Efficacy

Baclofen

Levodopa 411

Cannabinoids

Topical treatments

Lignocaine 5% medicated plaster

Capsaicin 412

Mechanism of action

Efficacy

Non-pharmacological therapy

Transcutaneous electrical nerve stimulation (TENS)

Spinal cord stimulation (SCS) 413

Sympathetic nerve blocks

Neurosurgical destructive techniques

Cognitive behaviour therapy

References 414

CHAPTER 23 – PRINCIPLES OF WOUND HEALING

Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann

Introduction 423

Phases of acute wound healing

Haemostasis

- Inflammation 426
 - Neutrophils 427
 - Macrophages 428
- Proliferative phase 429
 - Fibroblast migration 430
 - Collagen and extracellular matrix production
 - Angiogenesis 431
 - Granulation 432
 - Epithelialization
 - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
 - Normal and pathological responses to injury
 - Biochemical differences in the molecular environments of healing and chronic wounds 436
 - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
 - Role of endocrine hormones in the regulation of wound healing
 - Molecular basis of chronic non-healing wounds
 - Chronic venous stasis ulcers 441
 - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
 - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

Andrew Bradbury

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
 - New varicose veins
 - Persistent varicose veins
 - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

Michael Stacey

- Definitions 459**
 - Chronic venous insufficiency
 - Leg ulceration
 - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
 - Venous abnormality
 - Effect of ambulatory venous hypertension on the tissues in the leg 463
 - Influence of venous disease on the wound healing process 465
 - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
 - Compression therapy
 - Dressings 468
 - Surgery
 - Prevention of venous ulcer recurrence 470
 - Sclerotherapy and other techniques to obliterate surface and perforating veins
 - Other therapies 471
- References**

CHAPTER 26 –
PATHOPHYSIOLOGY AND
PRINCIPLES OF MANAGEMENT
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
 - Structural abnormalities/gait abnormalities
 - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
 - Neurological examination 479
 - Monofilament testing
 - Vibration testing
 - Dermatologic examination 480
 - Anatomy of occlusive disease – vascular examination
 - Prediction of wound healing: assessment of perfusion 481
 - Arterial imaging
 - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
 - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
 - Epidemiology and risk factors
 - Offloading
 - Non-vascular surgical treatment 485
 - Class I – Elective 486
 - Class II – Prophylactic
 - Class III – Curative
 - Class IV – Emergency (urgent)
 - Post-operative management
 - Infections 487
 - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA
– PRINCIPLES, GENETICS AND
PATHOPHYSIOLOGY

Matt Waltham

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
 - Lymphoedema – distichiasis syndrome 501
 - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
 - Meige disease (primary non-syndromic lymphoedema)
 - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT
MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
 - Healing of prosthetic grafts 512
 - The healing process of the anastomosis
 - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
 - Anastomotic compliance mismatch
 - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
 - Modifications and newer developments of PTFE grafts 517
 - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
Prosthetic graft modifications	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
Endothelial cell seeding	522
Single stage seeding	
Two stage seeding	
Vascular tissue engineering	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
Graft materials for aortic endografts	526
The future	
References	527

CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

Mauro Vicaretti

Introduction	537
Natural history of prosthetic vascular graft infections	
Mechanism of graft contamination at operation	538
Pathogenesis of graft infections	
Bacteriology of vascular graft infections	
Investigations for detection of prosthetic graft infections	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
Management of prosthetic graft infections	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
Established infection	
Antibiotic therapy	
Operative management	
Conclusion	542
References	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

29 • Pathophysiology of Vascular Graft Infections

MAURO VICARETTI

Department of Vascular Surgery, Westmead Hospital, Sydney, NSW, Australia.

INTRODUCTION

The introduction of prosthetic grafts has revolutionised the management of vascular disease but graft infection although uncommon, remains a dreaded complication with associated significant morbidity and mortality. Mortality occurs in approximately one third of all vascular graft infections,¹ with mortality highest when an aortic prosthesis is involved.^{2,3} As many as 75% of survivors of an infected aortic prosthesis require amputation of a limb,³ with the incidence of amputation highest when the infection involves more distal prosthetic grafts.⁴ The incidence of graft infections is difficult to quantify as infection may manifest many years after implantation¹ with many reports being isolated or as part of case series. Nevertheless, the reported incidence is in the order of 5%, varying according to the site of operation, being higher when a groin incision is used, or if the procedure is an emergency or a redo procedure. Infection following endovascular stent deployment has been reported although its incidence is considered to be very low.

NATURAL HISTORY OF PROSTHETIC VASCULAR GRAFT INFECTIONS

Early prosthetic vascular graft infections typically occurring in the first four months following placement are relatively uncommon (approximately 1%) and are usually caused by the more virulent micro-organisms, such as *S. aureus*, *E. Coli*, *Pseudomonas*, *Klebsiella*, *Proteus* and *enterobacter*.¹ Late prosthetic vascular graft infections are the result of two possible mechanisms. Firstly, by haematogenous seeding from a septic focus elsewhere⁵ or by the prosthetic graft becoming infected with enteric contents following a graft-enteric erosion.⁶ In both the haematogenous and graft-enteric erosion situations the usual causative organisms are those with high virulence and clinical manifestations are signs and symptoms of sepsis. The second mode of presentation is insidious, caused by the less virulent coagulase negative staphylococci such as *S. epidermidis* with contamination likely occurring at the time of implantation.¹

MECHANISMS OF GRAFT CONTAMINATION AT OPERATION

Prosthetic grafts most commonly become infected at the time of implantation either by contamination from the surgical team or by colonised microorganisms on the patient. It has been demonstrated that the majority of patients undergoing arterial revascularisation are colonised with coagulase negative staphylococci⁷ and colonisation of patients with nosocomial bacteria is enhanced when the preoperative hospitalisation is lengthy.⁸

The incidence of infection following emergency aneurysmorrhaphy has been reported to be increased to 7.5%.⁹ The evidence of other potential mechanisms such as division of lymph nodes,^{10,11,12} infected transudated fluid during aortic surgery^{13,14,15} and infected laminated thrombus^{4,14,16,17} is conflicting.

PATHOGENESIS OF GRAFT INFECTIONS

The exact aetiology of vascular graft infections is not completely understood but is likely to be multifactorial. According to Bandyk and Esses¹⁸ the risk of vascular graft infection as demonstrated by animal models can be predicted by the formula:

$$\text{Risk of biomaterial infection} = \frac{\text{Dose of bacterial contamination} \times \text{virulence}}{\text{Host resistance}}$$

The dose of bacterial contamination is dependent on the infecting microorganism. Experimentation in a canine aortic model has demonstrated that the infective threshold for bacteria to cause graft infection in over 50% of grafts was 10^7 , 10^9 , and 10^2 for *S. aureus*, *S. epidermidis* and *P. aeruginosa* respectively.¹⁹ Virulence of microorganisms is often associated with the production of secreted toxins

and enzymes with a resultant decline in structural integrity of the artery wall¹⁸ and the release of toxins and enzymes to control the perigraft environment and cause graft infection.^{19,20} Many bacterial strains, including *S. epidermidis*, *S. aureus* and *P. aeruginosa* are known to produce extracellular polymer substances (slime), forming a capsule incorporating the bacteria. This is referred to as a biofilm and protects the micro-organism against host defences and antibiotic therapy.²¹ Biofilms allow greater adherence of the microorganism to the biomaterial^{22, 23} and contribute to bacterial virulence. Multiple species of microorganisms may co-exist in a biofilm and unless the biofilm is disrupted and or the microorganism/s become planktonic the microorganism/s identification is limited. Different graft materials have varying susceptibility to infection. Dacron grafts are more likely to become infected than grafts made of PTFE (polytetrafluoroethylene).²⁴ The use of vein grafts instead of prosthetic material greatly reduces the risk of infection.

BACTERIOLOGY OF VASCULAR GRAFT INFECTIONS

Gram-positive, Gram-negative, anaerobic and fungal micro-organisms all have the potential to infect a vascular prostheses but in general the majority of infections are the result of a small number of micro-organisms. Staphylococci are the most prevalent organism associated with prosthetic graft infection.^{2,25,26,27} Of the staphylococci, *S. aureus* is generally regarded as the most common causative bacteria,^{2,26,28,29} particularly MRSA.²⁷ *S. epidermidis* is now being recognised as the leading cause of vascular graft infection, particularly chronic and late onset infections.^{17,29,30,31,32}

The Gram-negative organisms, *E. Coli*, *Pseudomonas*, *Klebsiella*, *Enterobacter* and *Proteus*, although relatively uncommon

causative organisms for graft infections are of particular interest and concern because of their high virulence and their tendency to destroy the vessel wall.^{18,33,34}

Candida mycobacterium, and *Aspergillus* infections are uncommon but pose a significant risk to patients who are immunocompromised.² Although uncommon they are all expected to increase in frequency because of their increasing resistance to standard prophylactic antibiotics.³⁵

There is an association between the type of infecting organism, the type of vascular complication and the arteries that are involved in the anastomosis to the prosthetic graft. Bandyk and Bergamini² in a collective survey of 1258 patients who had a vascular graft infection found that the majority of aortoenteric fistulas were the result of either *Streptococci* or *E. Coli* and if the anastomosis involved the femoral artery, the thoracic aorta, the subclavian, carotid or innominate arteries *S. epidermidis* or *S aureus* was the likely causative organism. *E. Coli*, *Enterococci* and *Enterobacter* were the more likely organisms to be involved in aortoiliac anastomoses.

INVESTIGATIONS FOR DETECTION OF PROSTHETIC GRAFT INFECTIONS

The diagnosis of vascular prosthetic infections can be difficult as the presentation may be subtle especially if it is a late onset infection, the prosthesis is intra-abdominal and the micro-organism is one of low virulence. Presentation is thus very dependent on the location of infection and the causative microorganism/s. The diagnosis is aided by multiple available microbiological investigations and imaging but in general is directed more at proving the absence of infection rather its presence. Not only are investigations imperative in the diagnosis of

vascular graft infection but they may assist in the planned therapy including vascular reconstruction when required. At times the only means of confirming graft infection is the surgical excision of the graft and further microbiological assessment.

History and physical examination

The clinical clues suggesting graft infection especially those placed superficially include an inflammatory perigraft mass, overlying cellulitis, presence of exposed prosthetic graft, a sinus tract with persistent purulent drainage and/or bleeding and/or a palpable anastomotic pseudoaneurysm, graft thrombosis and distal septic embolisation.^{2-4,36,37} The presence of intra-abdominal prosthetic graft infection may be non-specific, such as fever of unknown origin, septicaemia, or abdominal pain.³ Upper or lower gastrointestinal haemorrhage either of an acute or chronic nature may indicate a graft-enteric fistula^{17,37,38} and can only be excluded when another source of gastrointestinal haemorrhage has been identified.

Laboratory investigations

Routine laboratory studies such as white cell count and differential, erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP), and blood cultures are routinely obtained but the results may be non-specific and even normal if the organism is *S.epidermidis*.² Wherever possible pus, exudates, tissue specimens, blood and wound cultures should be analysed microbiologically to aid in microorganism identification and to allow the commencement of appropriate and specific chemotherapy.³⁹ To aid in the diagnosis of *S.epidermidis* all solid material should be mechanically or ultrasonically disrupted.⁴⁰⁻⁴²

Diagnostic imaging

Various diagnostic modalities (Computerised Tomography (CT), ultrasonography, Magnetic Resonance Imaging, Leucocyte or immunoglobulin labelled scanning, Positron Emission Tomography (PET) scanning +/- CT, angiography and/or endoscopy) may assist the vascular surgeon in determining the presence and extent of prosthetic graft infection. Not infrequently, a combination of the diagnostic modalities to improve sensitivity and specificity are utilised to confirm the presence or absence of a vascular prosthetic graft infection.⁴³ These modalities are also helpful in planning definitive surgery. The utility of CT angiography with the capability of vascular three dimensional reconstructions has largely replaced digital subtraction angiography as the method of diagnosis and therapeutic planning. CT guided aspiration is also of benefit in diagnosis. In general the features suggestive of graft infection include perigraft fluid and/or gas, graft disruption, absence of graft incorporation, pseudoaneurysm formation. The presence of periprosthetic gas more than six weeks following graft implantation is an abnormal finding and should alert the physician to the likelihood of a graft infection.⁴⁴

MANAGEMENT OF PROSTHETIC GRAFT INFECTIONS

The general principles in the management of prosthetic graft infections are initially preventative, but in the event of a vascular graft infection, therapy needs to be individualised accounting for clinical findings, graft material (prosthetic versus autogenous graft material), site of infection, microorganism/s involved and patient co-morbidities. It is imperative that not only is graft infection eradicated but recurrent infection be minimised with avoidance of significant morbidity and/or mortality.

Prevention

Preventive measures such as the routine use of skin preparations,⁴⁵ the use of a depilatory agent,⁴⁶ limiting the length of preoperative hospitalisation,⁸ operating time and intensive care stay all contribute to the reduction in wound infection and more importantly the chance of developing resistant multiple nosocomial infections.⁴⁵ Antimicrobial prophylaxis has been shown to reduce wound infections in vascular surgery⁴⁷ and ideally should be given as close to the time of incision and repeated in the event of haemorrhage and lengthy operations every four hours. Prophylactic antibiotics are also indicated with percutaneous punctures of existing prosthetic grafts and the implantation of stents. Decolonisation of nasal carriers of *S. aureus* has been shown to significantly reduce the number of surgical site *S. aureus* infections especially deep surgical-site infections.⁴⁸ Institutional prevalence of resistant organism may also dictate antibiotic prophylaxis especially when prosthetic grafts are to be implanted.

As a preventive measure host resistance may be enhanced by the antimicrobial impregnation of grafts. A number of novel combinations of grafts and antibiotic with or without various forms of treatment have been trialled at both the *in-vitro* and *in-vivo* levels.

Rifampicin, a known anti-staphylococcal agent, particularly methicillin resistant,⁴⁹ is a hydrophobic semisynthetic substance with a high affinity for gelatin.⁵⁰ It inhibits DNA dependent RNA polymerase activity in bacterial cells without affecting mammalian cells⁵¹ and has been passively incorporated into gelatin sealed Dacron grafts as a mode of staphylococcal protection at the time of implantation. It has been shown to be resistant to experimental bacterial contamination⁵²⁻⁵⁵ with in-vivo bioactivity

to 22 days,⁵⁶ and *in-vitro* bioactivity to 4 days.⁵⁷⁻⁵⁹ It is these qualities plus its excellent tissue and intracellular penetration⁵⁹ that make rifampicin an ideal antibiotic to be bonded to prosthetic grafts in order to prevent subsequent graft infection.

Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron

Using an established sheep model⁶⁰ we replaced a segment of sheep carotid artery with a rifampicin soaked Gelsoft graft. At the time of graft removal microscopic assessment (perigraft abscess formation, presence of anastomotic disruption and graft thrombosis) and microbiological assessments (cultures of perigraft tissues, graft external and internal wall and total graft cultures) were recorded. We showed that, following direct inoculation of the rifampicin (1.2mg/ml or 10mg/ml) soaked graft with 10^8 colony forming units of either methicillin resistant *Staphylococcal aureus* (MRSA) or methicillin resistant *Staphylococcal epidermidis* (MRSE), the rifampicin soaked graft offered significant prophylaxis.⁶¹⁻⁶³

For the MRSE arm, in the 10mg/ml rifampicin group there was a significant reduction in graft infection when compared to both the control group ($p < 0.05$) and the 1.2mg/ml group ($p < 0.05$).⁶³ Similarly, for the MRSA group, in the 10mg/ml treatment group there was a significant reduction in the total number of positive cultures when compared to the control group ($p < 0.05$) and the 1.2mg/ml group ($p < 0.05$).⁶³

ESTABLISHED INFECTION

Antibiotic therapy

Once the diagnosis or suspicion of prosthetic vascular graft infection is made then broad

spectrum antimicrobial therapy is initiated and subsequently converted to organism specific antibiotics.³ The length of antibiotic therapy following excision of the infected graft is unclear but Bergamini and Bandyk² advocate parenteral antibiotics for two weeks and oral for six months.

Operative management

The 'gold standard' treatment although technically challenging is the removal of all infected tissue and revascularisation extra-anatomically.⁶⁴ A number of more conservative approaches have been advocated depending on the site of the infection and the microorganism involved. The most conservative of treatments is aggressive local wound care with graft preservation (prosthetic/autologous) providing that the graft and anastomoses are intact and the patient has no systemic features of sepsis.⁶⁵ Calligaro *et al*³⁴ in a report of a series of patients who had graft preservation concluded that with the exception of *Pseudomonas*, vascular graft infections could be managed with debridement, antibiotic therapy and wound closure. The skeletonized prosthetic graft can be covered using viable regional rotational flaps.⁶⁶ Others have proposed graft excision and replacement with cadaveric arterial allografts,⁶⁷ venous autografts,⁶⁸ cryopreserved saphenous vein homografts,⁶⁹ autogenous arteries and/or veins⁷⁰ or prosthesis.⁷¹ The major drawback with in-situ reconstruction is recurrent graft sepsis⁷² with potential limb and/or life threatening graft and/or anastomotic disruption.

Schmitt, *et al*.²² in an *in-vitro* model comparing the bacterial adherence of four strains of bacteria (*S. aureus*, 'mucin' and 'non-mucin' producing *S. epidermidis* and *E. coli*) to ePTFE, woven Dacron and velour knitted Dacron found that bacterial adherence was greatest to velour knitted Dacron

and least compared to ePTFE. In addition Schmitt, *et al.*⁷³ found that 'mucin' producing *S. epidermidis* adhered to Dacron in 10 to 100 fold greater numbers compared to PTFE. Bandyk and Bergamini² have postulated that the differential adherence of staphylococci relates to capsular adhesins.

Using the established sheep model⁶⁰ we have set out to determine if the replacement of a staphylococcal infected vascular graft with a graft impregnated with rifampicin would be considered appropriate surgical management in preventing early recurrent infection. Gelsoft grafts without any antibiotic treatment were infected with overwhelming concentrations of either MRSA or MRSE. The grafts were removed at three weeks and replaced with either control (no rifampicin) grafts or grafts soaked in either 1.2mg/ml or 10mg/ml of rifampicin. The replacement grafts were removed 3 weeks following placement.

For MRSA⁷⁴ there were no statistical significant differences between the groups for any of the macroscopic or microbiological parameters recorded.

For *S. epidermidis*⁷⁴ there were no statistical differences between the rifampicin concentrations for macroscopic findings. There were however, statistically significant reductions in the number of total infected specimens in the 10mg/ml group when compared to both the control, ($p < 0.001$) and the 1.2 mg/ml groups ($p < 0.005$).⁷⁴

The conclusions from the studies⁷⁴ were that established *S. epidermidis* bacterial biofilm graft infections model can be treated by the in-situ replacement of the infected prosthesis with a 10mg/ml rifampicin impregnated Gelsoft graft. However, such management for MRSA established infections cannot be recommended from the results obtained in this particular animal model.

To date a number of groups^{75,76} have successfully managed prosthetic graft infections

with rifampicin impregnated grafts with zero mortality, no requirement for limb amputation and to date no recurrence of infection.

CONCLUSION

The future management of vascular graft infections will be reliant on a better understanding of the interaction between the micro-organism, the prosthesis and the immune system. This will allow a more directed approach towards prevention and treatment. Possibilities would include more powerful antibiotics either administered parenterally or incorporated into the prosthesis, acting as a local delivery system for prolonged periods of time. The role of the biofilm in the pathogenesis of graft infection needs further understanding from both a molecular and an immune level.

REFERENCES

1. Back MR and Klein SR. Infections and Antibiotics in Vascular Surgery. In: White RA and Hollier LH, (Eds). *Vascular Surgery: Basic Science and Clinical Correlations*. Philadelphia: J. B. Lippincott Company, 1994: 613–624.
2. Bandyk DF and Bergamini TM. Infection in prosthetic vascular grafts. In: Rutherford RB (Ed), *Vascular Surgery (4th ed.)*. Philadelphia: W. B. Saunders Company, 1995: 588–604.
3. Moore WS and Deaton DH. Infection in Prosthetic Vascular Grafts. In: Moore WS (Ed), *Vascular Surgery: A Comprehensive Review (4th ed.)*. Philadelphia: W. B. Saunders, 1993: 694–706.
4. Buckels JA and Wilson SE. Prevention and Management of prosthetic Graft Infection. In: Veith FJ, Hobson II RW,


- Williams RA and Wilson SE (Eds), *Vascular Surgery: Principles and Practice (2nd ed.)*: New York: McGraw-Hill Inc, 1994: 1081–1089.
5. Moore WS and Cole CW Infection in Prosthetic Vascular Grafts. In: Moore WS (Ed), *Vascular Surgery: A Comprehensive Review (3rd ed.)*: Philadelphia: W. B. Saunders, 1991: 598–609.
 6. Seabrook GR. Pathobiology of graft infections. *Seminars in Vascular Surgery* 1990; **3**: 81–88.
 7. Levy MF, Schmitt DD, Edmiston CE, Bandyk DF, Krepel CJ, Seabrook, GR, and Towne JB. Sequential analysis of staphylococcal colonization of body surface cultures on patients undergoing vascular surgery. *J Clin Micro* 1990; **28**: 664–669.
 8. Perry MO. Infection in vascular surgery. In: Davis JM and Shires GT (Eds), *Principles and Management of Surgical Infections* Philadelphia: J. B. Lippincott, 1991: 371–382.
 9. Jamieson G, DeWeese J, and Rob C. Infected arterial grafts. *Ann Surg* 1975; **181**: 850–852.
 10. Bunt TJ. Synthetic vascular graft infections. II. Graft-enteric erosions and graft-enteric fistulas. *Surg* 1983b; **94**: 1–9.
 11. Bouhoutos J, Chavatzas D, Martin P, and Morris T. Infected synthetic arterial grafts. *BJS* 1974; **61**: 108–111.
 12. Rubin JR, Malone JM, and Goldstone J. The role of the lymphatic system in acute arterial prosthetic graft infections. *J Vasc Surg* 1985; **2**: 92–97.
 13. Russell HE, Barnes RW, and Baker WA. Sterility of intestinal transudate during aortic reconstructive procedures. *Arch Surg* 1975; **110**: 402–404.
 14. Ernst CB, Campbell HC, Daugherty ME, Sachatello CR and Griffin WO. Incidence and significance of intraoperative bacterial cultures during abdominal aortic aneurysmectomy. *Ann Surg* 1977; **85**: 626–633.
 15. Scobie K, McPhail N, Barber G, and Elder R Bacteriologic monitoring in abdominal aortic surgery. *Can J Surg* 1979; **22**: 368–371.
 16. Brandimarte C, Santini C, Venditti M et al. Clinical significance of intraoperative cultures of aneurysm walls and contents in elective abdominal aortic aneurysmectomy. *Eur J Epidemiology* 1989; **5**: 521–525.
 17. O'Brien T and Collin J. Prosthetic vascular graft infection. *BJS* 1992; **79**: 1262–1267.
 18. Bandyk DF and Esses GE.. Prosthetic graft infection. *Surgical Clinics of North America* 1994; **74**: 571–590.
 19. White JV, Nessel CC and Whang K. Differential effect of type of bacteria on peripheral graft infections. In: Calligaro KD and Veith FJ (Eds), *Management of infected arterial grafts* St Louis: Quality Medical Publishing Incorporated, 1994: 25–42.
 20. Cohen JO. Staphylococcus. In: Baron S (Ed), *Medical Microbiology (3rd ed)* New York: Churchill Livingstone, 1991: 203–214.
 21. Richards GK and Gagnon RF. An assay of Staphylococcus epidermidis biofilm responses to therapeutic agents. *The International Journal of Artificial Organs* 1993; **16**: 777–787.
 22. Schmitt DD, Bandyk DF, Pequet AJ and Towne JB. Bacterial adherence to vascular prostheses. A determinant of graft infectivity. *J Vasc Surg* 1986b; **3**: 732–740.

23. Malangoni MA, Livingston DH and Peyton MS. The Effect of Protein Binding on the Adherence of Staphylococci to Prosthetic Vascular Grafts. *J Surg Res* 1993; **54**: 168–172.
24. Sugarman B. In- Vitro adherence to bacteria to prosthetic vascular grafts: *Infection* 1982; **10**: 9–14.
25. Lorentzen JE, Nielson OM, Arendrup H et al. Vascular graft infection: An analysis of sixty-two infections in 2411 consecutively implanted synthetic vascular grafts. *Surg* 1985; **98**: 81–86.
26. Golan JF. Vascular graft infection. *Infectious Disease Clinics of North America* 1989; **3**: 247–258.
27. Fletcher JP, Dryden M and Sorrell TC. Infection of vascular prosthesis. *Aust NZ J Surg* 1991; **61**: 432–435.
28. Bunt TJ. Synthetic vascular graft infections. I. Graft infections. *Surg* 1983a; **93**: 733–746.
29. Bandyk DF. Vascular graft infection. In: Bernhard VM and Towne JB (Eds), *Complications in Vascular Surgery, (2nd Ed)* Orlando: Grune and Stratton, 1985: 471–485.
30. Bandyk DF, Berni GA, Thiele BL, and Towne JB. Aortofemoral graft infection due to staphylococcus epidermidis. *Arch Surg* 1984; **119**: 102–108.
31. Bandyk DF. Vascular graft infections: Epidemiology, microbiology, pathogenesis and prevention. In: Bernhard VM and Towne JB (Eds). *Complications in Vascular Surgery, (2nd Ed)* St Louis: Quality Medical Publishing, 1991: 223–234.
32. Calligaro KD, Westcott CJ, Buckley RM, Savarese RP and DeLaurentis DA. Infrainguinal anastomotic arterial graft infections treated by selective graft preservation. *Ann Surg* 1992a; **216**: 74–79.
33. Geary KJ, Tomkiewicz AM, Harrison HN et al. Differential effects of a gram- negative and a gram-positive infection on autogenous and prosthetic grafts. *J Vasc Surg* 1990; **11**: 339–347.
34. Calligaro KD, Veith FJ, Schwartz ML, Savarese RP and DeLaurentis DA. Are gram-negative bacteria a contraindication to selective preservation of infected vascular grafts. *J Vasc Surg* 1992c; **16**: 337–346.
35. Treiman GS. Bacteriology of aortic graft infections. In: Gewartz BL and Schwartz LB (Eds.), *Surgery of the Aorta and its Branches* Philadelphia: W. B. Saunders Company, 2000: 375–383.
36. Goldstone J and Moore WS. Infection in vascular prosthesis. Clinical manifestations and surgical management. *Am J Surg* 1974; **128**: 225–233.
37. Murray SP, and Goldstone J. Diagnostic Advances. In: Calligaro KD and Veith FJ (Eds), *Management of infected arterial grafts* St Louis: Quality Medical Publishing Incorporated, 1994: 43–53.
38. Goldstone J and Cunningham C. Diagnosis, treatment, and prevention of aorto-enteric fistulas. *Acta Chirurgica Scandinavica Supplement* 1990; **555**: 165–172.
39. Gröschel DHM and Strain BA. Arterial Graft Infections From a Microbiologist's View: In Calligaro KD and Veith FJ (Eds), *Management of infected arterial grafts* St Louis: Quality Medical Publishing Incorporated, 1994: 3–15.
40. Tollefson ED, Bandyk DF, Kaebnick HW, Seabrook GR and Towne JB. Surface biofilm disruption.

- Enhanced recovery of microorganisms from vascular prosthesis. *Arch Surg* 1987; **122**: 38–43.
41. Bergamini TM, Bandyk DF, Govostis D, Kaebnick HW and Towne JB. Infection of vascular prostheses caused by bacterial biofilms. *J Vasc Surg* 1988; **7**: 21–30.
 42. Bergamini TM, Bandyk DF, Govostis D, Vetsch R and Towne JB. Identification of Staphylococcus epidermidis vascular graft infections. A comparison of culture techniques. *J Vasc Surg* 1989; **9**: 665–70.
 43. Bruggink JL, Glaudemans AW, Saleen BR, Meerwaldt R, Alkefai H, Prins TR, Slart RH, Zeebregts CJ. Accuracy of FDG-PET-CT in the diagnostic work-up of vascular prosthetic graft infection. *Eur J Vasc Endovasc Surg* 2010 Sep; **40**: 348–54.
 44. Qvarfordt PG, Reilly LM, Mark AS, Goldstone J, Wall SD, Ehrenfeld WK and Stoney RJ. Computerized tomographic assessment of graft incorporation after aortic reconstruction. *Am J Surg* 1985; **150**: 227–231.
 45. Cruse PJ and Foord R. A five year prospective study of 23,649 surgical wounds. *Arch Surg* 1973; **107**: 206–210.
 46. Seropian R and Reynolds BM. Wound infections after preoperative depilatory versus razor preparation. *Am J Surg* 1971; **121**: 251–4.
 47. Bandyk DF, Bergamini TM, Kinney EV, Seabrook GR and Towne JB. In situ replacement of vascular prosthesis infected by bacterial biofilms. *J Vasc Surg* 1991; **13**: 575–583.
 48. GMB Lonneke, Kluytmans JA, Wertheim HF, Bogaers D et al. Preventing Surgical-Site Infections in Nasal Carriers of Staphylococcus aureus. *NEJM* 2010; **362**: 9–17.
 49. Turnbridge J and Grayson ML. Optimum Treatment of Staphylococcal Infections. *Drugs*, 1993; **45**: 353–366.
 50. Ashton TR, Cunningham JD, Patan D and Maini R. Antibiotic loading of vascular grafts. *Proceedings of the 16th Annual Meeting of the Society for Biomaterials* 1990; **13**: 235.
 51. Farr B and Mandell GL. Rifampicin. *Medical Clinics of North America* 1982; **66**: 157–168.
 52. Powell TW, Burnham SJ and Johnson G Jr. A passive system using rifampicin to create an infection resistant vascular prosthesis. *Surg* 1983; **94**: 765–769.
 53. MacDougal EG, Burnham SJ and Johnson G. Jr. Rifampicin protection against experimental graft sepsis. *J Vasc Surg* 1986; **4**: 5–7.
 54. Avramovic J R and Fletcher JP. Rifampicin Impregnation of a protein sealed Dacron graft: An Infection Resistant Vascular Graft. *Aust NZ J Surg* 1991; **61**: 436–440.
 55. Chervu A, Moore WS, Gelabert HA, Colburn M and Chvapil M. Prevention of graft infection by use of prosthesis bonded with a rifampicin/collagen release system. *J Vasc Surg* 1991; **14**: 521–525.
 56. Chervu A, Moore WS, Chvapil M and Henderson T. Efficacy and duration of antistaphylococcal activity comparing three antibiotics bonded to Dacron vascular grafts with a collagen release system. *J Vasc Surg* 1991; **13**: 897–901.
 57. Goeau-Brissonniere O, Leport C, Bacourt F, Lebrault C, Comte R Pechre JC. Prevention of vascular graft infection by rifampicin bonding to a Gelatin sealed Dacron graft. *Ann Vasc Surg* 1991; **5**: 408–412.

58. Lachapelle K, Graham AM and Symes JF. Antibacterial activity, antibiotic retention, and infection resistance of a rifampicin- impregnated gelatin- sealed Dacron graft. *J Vasc Surg* 1994; **19**: 675–82.
59. Gahtan V, Esses GE, Bandyk DF, Nelson RT, Dupont E and Mills JL. Antistaphylococcal activity of rifampicin- bonded gelatin- impregnated Dacron grafts. *Journal of Surgical Research* 1995; **58**: 105–110.
60. Fletcher JP, Dryden M, Munro B, Xu J H and Hehir MD. Establishment of a vascular graft infection model in the sheep carotid artery. *Aust NZJ Surg* 1990; **60**: 801–803.
61. Sardelic F, Ao PY, Taylor DA and Fletcher JP. Prophylaxis against *Staphylococcus epidermidis* vascular graft infection with rifampicin-soaked, gelatin-sealed Dacron. *Cardiovasc Surg* 1996; **4**: 389–92.
62. Fletcher JP, Avramovic JR, Kenny J and Sardelic, F. Increased resistance to *Staphylococcal* graft infection by rifampicin impregnation of gelatin sealed Dacron. In: Chang JB (Ed). *Modern Vascular Surgery (vol 6)* New York: Springer Verlag, 1994: (483–487).
63. Vicaretti M, Hawthorne, WJ, Ao PY and Fletcher JP. An increased concentration of rifampicin bonded to gelatin-sealed Dacron reduces the incidence of subsequent graft infections following a staphylococcal challenge. *Cardiovasc Surg* 1998; **6**: 268–73.
64. Curl GR and Ricotta JJ. Total Prosthetic Graft Excision and Extra-anatomic Bypass. In: Calligaro KD and Veith FJ (Eds), *Management of infected arterial grafts*. St Louis: Quality Medical Publishing Incorporated, 1994: (82–94)
65. Calligaro KD, Veith FJ, Schwartz ML, Savarese RP, Goldsmith J, Westcott CJ and DeLaurentis DA. (1992b). Management of infected lower extremity autologous vein grafts by selective graft preservation. *Am J Surg* 1992; **164**: 291–4.
66. Turnispeed WD and Dibbell DG Sr. Rotational Muscle Flaps in Localized Infections. In: Calligaro KD and Veith FJ (Eds.), *Management of infected arterial grafts* St Louis: Quality Medical Publishing Incorporated, 1994: (142–159).
67. Kieffer E, Bahnini A, Koskas F, Ruotolo C, Le Blevec D and Plissonier, D. In situ allograft replacement of infected infrarenal aortic prosthetic grafts: Results in forty three patients. *J Vasc Surg* 1993; **17**: 349–356.
68. Clagett GP, Bowers BL, Lopez-Viago MA, Rossi MB, Valentine RJ, Myers SI and Chervu, A. Creation of a neo-aortoiliac system from lower extremity deep and superficial veins. *Ann Surg* 1993; **218**: 239–249.
69. Fujitani RM, Bassinouny HS, Gewertz BL, Glagov S and Zarins CK. Cryopreserved saphenous vein allogenic homografts: An alternative conduit in lower extremity arterial reconstruction in infected fields. *J Vasc Surg* 1992; **15**: 519–526.
70. Seeger JM, Wheeler JR, Gregory RT, Snyder SO and Gayle RG. Autogenous graft replacement of infected prosthetic grafts in the femoral position. *Surg* 1983; **93**: 39–45.
71. Towne JB, Seabrook GR, Bandyk D, Freischlag JA and Edmiston CE. In situ-replacement of arterial prosthesis infected by bacterial biofilms: Long-term follow-up. *J Vasc Surg* 1994; **19**: 226–235.

72. Robinson JA and Johansen K. Aortic sepsis: Is there a role for in-situ graft reconstruction? *J Vasc Surg* 1991; **13**: 677–684.
73. Schmitt DD, Bandyk DF, Pequet AJ, Malangoni MA and Towne JB. Mucin production by *Staphylococcus epidermidis*. *Arch Surg* 1986; **121**: 89–95.
74. Vicaretti M, Hawthorne WJ, Ao PY and Fletcher JP. Does in-situ replacement of an infected vascular graft with a rifampicin soaked gelatin sealed dacron graft reduce the incidence of subsequent infection? *Intl Angio* 2000; **19**: 158–65.
75. Torsello G, Sandmann W, Gehrt A and Jungblut RM. In-situ replacement of infected vascular prosthesis with rifampicin- soaked vascular grafts: Early results. *J Vasc Surg* 1993; **17**: 768–773.
76. Naylor AR, Clark S, London NJ, Sayers RD, Macpherson DS, Barrie WW. Treatment of major aortic graft infection: preliminary experience with total graft excision and in situ replacement with a rifampicin bonded prosthesis. *Eur J Endovasc Surg* 1995; **9**: 252–6.



Cover diagram by David Heinrich of the *Medical Illustration and Media Unit, Flinders Medical Centre*. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

Chapter 1: Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press